PharmacyCodes



Ramiprilum [Latin] en es it fr

Categorie

Ramiprilum [Latin] Les marques, Ramiprilum [Latin] Analogs

Ramiprilum [Latin] Les marques melange

  • No information avaliable

    • Ramiprilum [Latin] Formule chimique

    C23H32N2O5

    Ramiprilum [Latin] RX lien

    http://www.rxlist.com/cgi/generic/ramipril.htm

    Ramiprilum [Latin] FDA fiche

    Ramiprilum [Latin] msds (fiche de securite des materiaux)

    Ramiprilum_[Latin] MSDS

    Ramiprilum [Latin] Synthese de reference

    EH Gold et coll., US. 4.587.258 (1967).

    Ramiprilum [Latin] Poids moleculaire

    416.511 g/mol

    Ramiprilum [Latin] Point de fusion

    109 oC

    Ramiprilum [Latin] H2O Solubilite

    3.5mg / L

    Ramiprilum [Latin] Etat

    Solid

    Ramiprilum [Latin] LogP

    3.149

    Ramiprilum [Latin] Formes pharmaceutiques

    Capsule

    Ramiprilum [Latin] Indication

    Pour les diurétiques et les digitaliques dans l'insuffisance cardiaque congestive tant que thérapie adjuvante et pour une utilisation en prophylaxie de post-IM.

    Ramiprilum [Latin] Pharmacologie

    Le ramipril est un inhibiteur de l'enzyme de conversion (IEC) similaire à bénazépril, le fosinopril, le quinapril et l'. Une prodrogue inactive, le ramipril est converti en ramiprilate dans le foie et est utilisé pour traiter l'échec d'hypertension et de cœur, afin de réduire la protéinurie et la maladie rénale chez les patients avec néphropathie, et de prévenir les AVC, infarctus du myocarde et décès d'origine cardiaque à haut risque des patients.

    Ramiprilum [Latin] Absorption

    Le degré d'absorption d'au moins 50-60% et n'est pas significativement influencée par la présence d'aliments dans le tractus gastro-intestinal, même si le taux d'absorption est réduite.

    Ramiprilum [Latin] Toxicite

    Les manifestations cliniques les plus probables seraient les symptômes attribuables à une hypotension. DL50 = 10933 mg / kg (par voie orale chez la souris).

    Ramiprilum [Latin] Information pour les patients

    Pregnancy: Female patients of childbearing age should be told about the consequences of second- and third-trimester exposure to ACE inhibitors, and they should also be told that these consequences do not appear to have resulted from intrauterine ACE-inhibitor exposure that has been limited to the first trimester. These patients should be asked to report pregnancies to their physicians as soon as possible.

    Angioedema: Angioedema, including laryngeal edema, can occur with treatment with ACE inhibitors, especially following the first dose. Patients should be so advised and told to report immediately any signs or symptoms suggesting angioedema (swelling of face, eyes, lips, or tongue, or difficulty in breathing) and to take no more drug until they have consulted with the prescribing physician.

    Symptomatic Hypotension: Patients should be cautioned that lightheadedness can occur, especially during the first days of therapy, and it should be reported. Patients should be told that if syncope occurs, ramipril should be discontinued until the physician has been consulted.

    All patients should be cautioned that inadequate fluid intake or excessive perspiration, diarrhea, or vomiting can lead to an excessive fall in blood pressure, with the same consequences of lightheadedness and possible syncope.

    Hyperkalemia: Patients should be told not to use salt substitutes containing potassium without consulting their physician.

    Neutropenia: Patients should be told to promptly report any indication of infection (e.g., sore throat, fever), which could be a sign of neutropenia.

    Ramiprilum [Latin] Organismes affectes

    Les humains et autres mammifères